Nina Shah

Pentagon Initiates Changes at Stars & Stripes, Raising Concerns Over Editorial Independence

Defense Department aims to reshape military newspaper amid fears of politicization and loss of journalistic autonomy

The Pentagon has announced plans to update Stars & Stripes, an independent newspaper serving U.S. military personnel globally, with a focus on elimina...

Senate Crypto Legislation Stalemate Weighs on Coinbase and Robinhood Shares

Uncertainty around key regulatory framework stalls potential growth avenues for major U.S. crypto exchanges

Shares of Coinbase Global Inc and Robinhood Markets Inc experienced notable declines following renewed concerns regarding the stalled Senate crypto ma...

Early Measles Detection via Wastewater Monitoring Offers Public Health Advantages

State programs face funding challenges despite evidence of efficacy in tracking contagious outbreaks

Recent studies by the Centers for Disease Control and Prevention highlight the effectiveness of wastewater surveillance in identifying measles presenc...

Cohen & Steers (CNS) - Upgrade to Long: Buy the Recovery, Back the Dividend and Product Momentum

Stable fees, improving cash flow, and a solid yield make CNS a tactical buy on pullbacks — entry, stop, and targets included.

We upgrade Cohen & Steers to a positive rating. The firm’s niche REIT-focused investing, $90.9B AUM base, recent quarter of $141.7M revenue and $0.8...

Dogecoin and Shiba Inu Experience Sharp Declines Despite Supply Reduction Efforts

Institutional outflows from Dogecoin and increased Shiba Inu token burns fail to arrest price drops amid waning retail demand

Dogecoin and Shiba Inu have each declined by approximately 5% recently, with institutional selling pressures and ineffective supply reduction mechanis...

Buy the Dip in Uber: Delivery Momentum + Cash Generation Make the Risk/Reward Attractive

UBER - Tactical long: enter on weakness, stop tight, target the next leg of re-rating as Eats and ad revenue accelerate

Uber’s latest results show accelerating revenue and strong cash generation even as some headline net-income moves are driven by tax/non-operating it...

Why I'm Upgrading ImmunityBio (IBRX) to Buy for 2026: A Risk-Weighted, Catalyst-Driven Trade

Revenue momentum, improving gross margin, and recent financing reduce near-term binary risk — but balance sheets and dilution keep this a high-risk biotech long.

ImmunityBio's recent quarters show accelerating revenue (Q1-Q3 2025: $16.5M -> $26.4M -> $32.1M), tiny cost of revenue and expanding gross profit, and...

Regions Financial Eyes Solid Q4 Performance Amid CFO Transition and Analyst Revisions

Consensus Forecasts Moderate Growth in Earnings and Revenue with Mixed Analyst Ratings Ahead of Upcoming Earnings Release

Regions Financial Corporation is set to disclose its fourth-quarter earnings results on January 16, with market expectations indicating modest improve...

Milestone Pharmaceuticals - Why 'Sell the News' After CARDAMYST Approval Is a Mistake

Approval is the start of a commercial story, not the finish line - balance sheet and pipeline support a tactical long.

Milestone (MIST) just cleared the biggest binary risk with FDA approval of CARDAMYST (etripamil). The market's reflexive 'sell the news' move ignores ...

Morgan Stanley Projects Strong 2026 IPO Activity and Expanding Deal Flow

Fourth-quarter 2025 earnings surpass expectations amid growth in advisory and wealth segments

Morgan Stanley reported robust fourth-quarter 2025 results including earnings per share of $2.68, surpassing analyst forecasts and demonstrating 18% y...